Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CHINA OILFIELD
02883
5
CNOOC
00883
HK Stock MarketDetailed Quotes
SHINEWAY PHARM (02877)
- 9.900
- -0.230-2.27%
Not Open Apr 24 16:07 CST
8.19BMarket Cap7.78P/E (TTM)
10.010High9.890Low432.00KVolume10.010Open10.130Prev Close4.30MTurnover0.05%Turnover Ratio7.78P/E (Static)827.00MShares10.47052wk High0.92P/B8.19BFloat Cap6.84052wk Low0.51Dividend TTM827.00MShs Float22.633Historical High0.505Dividend LFY1.19%Range %-6.264Historical Low9.949Avg Price1000Lot Size5.10%Div Yield TTM5.10%Div Yield LFY
SHINEWAY PHARM (02877) Income Statement
All
YOY
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -17.01%3.14B | -20.80%1.65B | -16.35%3.78B | -13.01%2.09B | 14.32%4.52B | 32.14%2.4B | 22.56%3.95B | 16.80%1.82B | 21.38%3.22B | 30.58%1.55B |
| Operating income | -17.01%3.14B | -20.80%1.65B | -16.35%3.78B | -13.01%2.09B | 14.32%4.52B | 32.14%2.4B | 22.56%3.95B | 16.80%1.82B | 21.38%3.22B | 30.58%1.55B |
| Cost of sales | 8.15%-869.21M | 10.77%-459.09M | 15.69%-946.29M | 13.49%-514.51M | -10.88%-1.12B | -21.28%-594.72M | -24.48%-1.01B | -20.47%-490.38M | -21.77%-813.21M | -29.74%-407.07M |
| Operating expenses | 8.15%-869.21M | 10.77%-459.09M | 15.69%-946.29M | 13.49%-514.51M | -10.88%-1.12B | -21.28%-594.72M | -24.48%-1.01B | -20.47%-490.38M | -21.77%-813.21M | -29.74%-407.07M |
| Gross profit | -19.97%2.27B | -24.08%1.19B | -16.57%2.83B | -12.85%1.57B | 15.51%3.39B | 36.17%1.8B | 21.90%2.94B | 15.50%1.32B | 21.25%2.41B | 30.88%1.15B |
| Selling expenses | 27.03%-1.17B | 20.74%-647.84M | 19.39%-1.6B | 20.27%-817.37M | -8.96%-1.98B | -24.29%-1.03B | -21.27%-1.82B | -17.45%-824.8M | -26.51%-1.5B | -24.99%-702.24M |
| Administrative expenses | 3.99%-279.69M | 12.92%-126.45M | 10.77%-291.32M | -4.95%-145.21M | -16.69%-326.5M | -8.13%-138.37M | -9.06%-279.8M | -13.23%-127.97M | 6.15%-256.56M | 10.65%-113.01M |
| Research and development expenses | -2.57%-103.1M | -12.59%-50.38M | 9.00%-100.52M | 7.16%-44.75M | 5.95%-110.46M | -68.11%-48.2M | -4.21%-117.45M | -14.57%-28.67M | -13.04%-112.71M | -24.03%-25.03M |
| Impairment and provision | -440.46%-35.74M | 142.81%1.84M | -21.54%-6.61M | 31.27%-4.29M | 38.38%-5.44M | -332.16%-6.24M | -25.74%-8.83M | -174.86%-1.44M | 97.03%-7.02M | 84.94%-525K |
| -Other impairment is provision | -440.46%-35.74M | 142.81%1.84M | -21.54%-6.61M | 31.27%-4.29M | 38.38%-5.44M | -332.16%-6.24M | -25.74%-8.83M | -174.86%-1.44M | -1.53%-7.02M | 84.94%-525K |
| Special items of operating profit | 57.76%199.57M | 4.52%191.48M | -24.42%126.51M | 535.09%183.19M | 59.44%167.38M | 117.03%28.85M | 26.71%104.98M | -45.53%13.29M | -3.85%82.85M | -69.69%24.4M |
| Operating profit | -8.40%881.64M | -24.40%562.25M | -15.38%962.5M | 20.97%743.76M | 38.96%1.14B | 73.09%614.85M | 32.62%818.56M | 7.44%355.23M | 121.25%617.22M | 35.01%330.63M |
| Financing cost | 7.24%-5.69M | -105.61%-5.86M | -123.93%-6.13M | -1,567.84%-2.85M | -334.44%-2.74M | 50.43%-171K | 49.76%-630K | 73.42%-345K | 92.45%-1.25M | 90.28%-1.3M |
| Special items of earning before tax | 107.71%393.31M | 80.15%218.29M | 79.46%189.35M | 114.05%121.17M | 6.47%105.51M | 0.15%56.61M | -4.84%99.1M | 10.64%56.53M | -21.50%104.14M | -27.30%51.09M |
| Earning before tax | 10.78%1.27B | -10.14%774.68M | -7.62%1.15B | 28.42%862.08M | 35.25%1.24B | 63.17%671.29M | 27.35%917.03M | 8.15%411.41M | 82.29%720.1M | 26.05%380.42M |
| Tax | -4.47%-319.32M | 32.08%-160.02M | -12.90%-305.67M | -31.02%-235.6M | -39.38%-270.74M | -123.98%-179.82M | -18.86%-194.25M | -11.56%-80.29M | -63.44%-163.43M | -49.65%-71.97M |
| After-tax profit from continuing operations | 13.08%949.95M | -1.89%614.66M | -13.35%840.05M | 27.47%626.48M | 34.14%969.51M | 48.42%491.47M | 29.84%722.77M | 7.35%331.12M | 88.68%556.67M | 21.57%308.46M |
| Earning after tax | 13.08%949.95M | -1.89%614.66M | -13.35%840.05M | 27.47%626.48M | 34.14%969.51M | 48.42%491.47M | 29.84%722.77M | 7.35%331.12M | 88.68%556.67M | 21.57%308.46M |
| Profit attributable to shareholders | 13.08%949.95M | -1.89%614.66M | -13.35%840.05M | 27.47%626.48M | 34.14%969.51M | 48.42%491.47M | 29.84%722.77M | 7.35%331.12M | 88.68%556.67M | 21.57%308.46M |
| Basic earnings per share | 13.51%1.26 | -2.41%0.81 | -13.28%1.11 | 27.69%0.83 | 33.33%1.28 | 47.73%0.65 | 29.73%0.96 | 7.32%0.44 | 89.74%0.74 | 24.24%0.41 |
| Diluted earnings per share | 13.51%1.26 | -2.41%0.81 | 1.11 | 27.69%0.83 | 47.73%0.65 | 29.73%0.96 | 7.32%0.44 | 89.74%0.74 | 24.24%0.41 | |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
| Auditor | Deloitte Touche Tohmatsu会计师事务所 | -- | Deloitte Touche Tohmatsu会计师事务所 | -- | Deloitte Touche Tohmatsu会计师事务所 | -- | Deloitte Touche Tohmatsu会计师事务所 | -- | Deloitte Touche Tohmatsu会计师事务所 | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"